Safety and Efficacy of Long-term Somatropin Treatment in Adults

NCT01543880 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 752

Last updated 2015-04-29

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of the study is to evaluate safety and efficacy in adults treated with somatropin (Norditropin®).

Conditions

  • Growth Hormone Disorder
  • Adult Growth Hormone Deficiency

Interventions

DRUG

somatropin

Prescribed at the discretion of the treating physician according to product labelling

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2013-12-31
Completion
2014-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01543880 on ClinicalTrials.gov